The latest price target for Telix Pharmaceuticals (NASDAQ:TLX) was reported by UBS on November 15, 2024. The analyst firm set a price target for $21.00 expecting TLX to rise to within 12 months (a possible 36.36% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Telix Pharmaceuticals (NASDAQ:TLX) was provided by UBS, and Telix Pharmaceuticals initiated their buy rating.

There is no last upgrade for Telix Pharmaceuticals

There is no last downgrade for Telix Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Telix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Telix Pharmaceuticals was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Telix Pharmaceuticals (TLX) rating was a initiated with a price target of $0.00 to $21.00. The current price Telix Pharmaceuticals (TLX) is trading at is $15.40, which is within the analyst’s predicted range.